OS1.F Otsuka Holdings Co. Ltd
- Market cap
- EUR 36.1B
- P/E
- 17.2x
- P/B
- 1.98x
- ROE
- 13.4%
- Dividend yield
- 1.65%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is OS1.F undervalued?
Graham numberOS1.F trades 23.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Otsuka Holdings Co. Ltd fundamental analysis
No fundamental analysis for Otsuka Holdings Co. Ltd yet.
Otsuka Holdings Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Otsuka Holdings Co. Ltd
Otsuka Holdings Co., Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. It develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, autoimmune space digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices. It also provides clinical testing, medical equipment and tools, food products, cosmetics, functional food products…
Full company profileOtsuka Holdings Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Otsuka Holdings Co. Ltd annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.20T | 1.24T | 1.29T | 1.40T | 1.42T | 1.50T | 1.74T | 2.02T | 2.33T | 2.47T | 2.72T |
| Gross Profit | 789B | 817B | 850B | 945B | 983B | 1.00T | 1.17T | 1.41T | 1.67T | 1.77T | 1.97T |
| Operating Income | 85.2B | 84.9B | 91.8B | 174B | 212B | 152B | 186B | 292B | 416B | 472B | 540B |
| EBITDA | - | 171B | 177B | 257B | 282B | 253B | 273B | 247B | 453B | 611B | 702B |
| Net Income | 92.6B | 112B | 82.5B | 127B | 148B | 125B | 134B | 122B | 343B | 363B | 429B |
| EPS | - | 208 | 152 | 234 | 273 | 231 | 247 | 224 | 639 | 688 | 820 |
| Balance Sheet | |||||||||||
| Total Assets | 2.48T | 2.48T | 2.48T | 2.58T | 2.63T | 2.82T | 3.10T | 3.36T | 3.74T | 4.20T | 4.32T |
| Total Liabilities | 740B | 658B | 744B | 786B | 744B | 776B | 840B | 925B | 961B | 1.10T | 1.04T |
| Shareholders' Equity | 1.71T | 1.79T | 1.70T | 1.77T | 1.85T | 2.01T | 2.23T | 2.39T | 2.73T | 3.03T | 3.22T |
| Cash & Short-term Investments | 370B | 337B | 285B | 334B | 357B | 411B | 472B | 513B | 426B | 535B | 472B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 142B | 103B | 136B | 229B | 229B | 229B | 212B | 227B | 355B | 404B | 446B |
| Capital Expenditure | 71.6B | 54.2B | 57.1B | 52.5B | 52.5B | 52.5B | 60.9B | 91.4B | 129B | 142B | 279B |
| Free Cash Flow | - | 25.3B | 62.2B | 129B | 135B | 116B | 104B | 135B | 225B | 262B | 167B |
| Ratios | |||||||||||
| ROE | 5.4% | 6.3% | 4.8% | 7.2% | 8.0% | 6.2% | 6.0% | 5.1% | 12.6% | 12.0% | 13.4% |
| ROA | 3.7% | 4.5% | 3.3% | 4.9% | 5.6% | 4.4% | 4.3% | 3.6% | 9.2% | 8.7% | 9.9% |
| Net Profit Margin | 7.7% | 9.1% | 6.4% | 9.1% | 10.4% | 8.4% | 7.7% | 6.0% | 14.7% | 14.7% | 15.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Otsuka Holdings Co. Ltd dividends
- Dividend yield
- 1.65%
- Forward dividend
- 1.13 EUR
- Payout ratio
- 19.5%
- Ex-dividend date
- Dec 29, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | JPY 71.0B | 134 | 19.5% |
| 2024 | JPY 66.8B | 124 | 19.5% |
| 2023 | JPY 55.7B | 103 | 45.8% |
| 2022 | JPY 55.6B | 102 | 41.5% |
| 2021 | JPY 56.0B | 103 | 44.6% |
| 2020 | JPY 56.0B | 103 | 37.8% |
| 2019 | EUR 56.0B | 103 | 44.0% |
| 2018 | EUR 55.3B | 102 | 67.0% |
| 2017 | EUR 54.9B | 101 | 48.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Otsuka Holdings Co. Ltd
- Insiders 4.89%
- Institutions 44.53%
- Public & others 50.58%
- Shares outstanding 524M
- Free float 444M
Otsuka Holdings Co. Ltd company profile
- Company name
- Otsuka Holdings Co. Ltd
- Ticker
- OS1.F
- ISIN
- JP3188220002
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 37,758
- Fiscal year end
- December
- Address
- 2-9 Kanda-Tsukasamachi, Chiyoda, Japan, 101-0048
- Phone
- 81 3 6717 1410
- Website
- otsuka.com
About Otsuka Holdings Co. Ltd
Otsuka Holdings Co., Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. It develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, autoimmune space digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices. It also provides clinical testing, medical equipment and tools, food products, cosmetics, functional food products, chemical products, soft drinks, beverages, analytical and measurement equipment, nutritional products, vehicle headlight testers, synthetic resin molded products, paper products, quasi-drugs, household products, and packaging materials and electronic parts. In addition, it offers IT solutions; adhesive tapes; flaky titanate and compounds; infusion and clinical nutrition products; hydrazine; plant-based food products; reinsurance underwriting services; wine; stable isotopes; food supplements; software and services for management of mental healthcare systems; anticancer drugs; terracess; bio-pesticides; dietetic food products; spring and mineral water; and polyolefin foams. Further, it engages in the warehousing and transport, medical device operational management, shared service, environmental health management, and venture capital and incubation businesses; rental of medical devices and related products; purchase and sale of agricultural products; import and export trading business; tuberculosis research and development activities; rental of space and office businesses; manufacturing and development of xenotransplantation products; and processing and marketing of functional films, as well as planning, design, production, and construction of ceramic boards and arts, ceramic walls, reliefs, terracotta, ceramic OT and portraits, and ceramic sign boards; and operation of travel agency, and Hotel Ridge and California Table. The company was founded in 1921 and is headquartered in Chiyoda, Japan.
Otsuka Holdings Co. Ltd management
10- Mr. Makoto InouePresident, CEO & Representative Director · born 1958
- Ms. Yuko MakinoCFO & Executive Director · born 1961
- Ms. Noriko TojoExecutive Director · born 1964
- Mr. Yoshiro MatsuoExecutive Deputy President & Representative Director · born 1960
- Mr. Masayuki KobayashiExecutive Director · born 1966
- Mr. Shuichi TakagiExecutive Director · born 1966
- Tomohiro Emura Ph.D.Executive VP & Operating Officer of IR, Public Relations, and Sustainability Promotion
- Chiaki SakuraiSenior EVP, Operating Officer & Dir. of Nutraceutical Bus., Global Strat. and Planning Headquarters
- Manabu KawataExecutive VP & Operating Officer of Business Development Department
- Keiso YamasakiExecutive VP, Operating Officer & Director of Corp. Planning Dept., Bus. Insights and Analytics